Document is current

Article History

Accepted: 22 August 2024

First Online: 16 September 2024

Declarations

:

: This work was funded in part by grants from the National Taiwan University Hospital, Hsin-Chu branch (113-HCH013, 113-HCH106, and NHRI-113-H06), the Ministry of Science and Technology of Taiwan (MOST 109-2314-B-182A-012, MOST 110-2314-B-182A-104, MOST111-2314-B-182A-116, MOST 111-2314-B-002-244, NSTC 112-2314-B-002-073-MY3), and Chang Gung Memorial Hospital (CMRPG1N0131, CMRPG1F0161, CFRPG1M0011). The funders had no role in the study design, data collection and analysis, interpretation of findings, manuscript writing, or target journal selection.

: All authors have completed the ICMJE uniform disclosure form available at and declare the following: HYC has received speaking fees from AbbVie, Novartis, Janssen-Cilag, Eli-Lilly, Kyowa Hakko Kirin Taiwan, Boehringer Ingelheim, Bristol Myers Squibb, and Pfizer and has conducted clinical trials for Eli-Lilly, AbbVie, Janssen-Cilag, and Sanofi Pharmaceuticals. YHH has conducted clinical trials while serving as a principal investigator for Galderma, Eli-Lilly, Novartis Pharmaceuticals Corporation, and Janssen-Cilag Pharmaceutica, has received honoraria for serving as an advisory board member for Pfizer Limited, AbbVie, and Celgene and has received speaking fees from AbbVie, Eli-Lilly, and Novartis Pharmaceuticals Corporation. CNL has received speaking fees from Janssen-Cilag Pharmaceutica, Sanofi, and Novartis. NLW has conducted clinical trials for Novartis, Pfizer, Galderma, and Bristol-Myers Squibb and has received speaking fees from Pfizer, Novartis, AbbVie, Janssen-Cilag, Eli-Lilly, and Sanofi Pharmaceuticals. RCYH has received speaking fees from AbbVie, Novartis Pharmaceuticals Corporation, Janssen-Cilag Pharmaceutica, Eli-Lilly, Kyowa Hakko Kirin Taiwan, and Pfizer Limited and has conducted clinical trials for Eli-Lilly and Sanofi Pharmaceuticals. TFT has conducted clinical trials or received honoraria for serving as a consultant or speaking fees from Pfizer Limited, Serono International SA (now Merck Serono International SA), UniPharma/Biogen Idec, Galderma, Celgene, Novartis Pharmaceuticals Corporation, Kyowa Hakko Kirin Taiwan, Boehringer Ingelheim, Bristol Myers Squibb, Janssen-Cilag Pharmaceutica, and AbbVie. TFT is an Editorial Board member of the <i>American Journal of Clinical Dermatology</i>. TFT was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. SJH and CMH have no conflicts of interest that are directly relevant to the content of this article.

: The study protocol was reviewed and approved by the local Institutional Review Board of the National Taiwan University Hospital, Hsin-Chu branch (103-082-E, 109-005-E); Chang Gung Memorial Hospital, Linkou and Taipei branches (202000677B0); Hualien Tzu Chi Hospital (P00003100); National Cheng Kung University Hospital (AB-CR-110-021); MacKay Memorial Hospital (23MMHIS248e); National Taiwan University Hospital (201605118RINB, 201904124RINC).

: Not applicable.

: Not applicable.

: The data underlying this article are available in the article and in its online supplementary material.

: Not applicable.

: All authors contributed to the concept and design; acquisition, analysis, or interpretation of the data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; and statistical analysis. HYC and YHH contributed to obtaining funding. All authors contributed to administrative, technical, or material support, and study supervision; provided critical feedback on the manuscript, approved the final manuscript for submission, and are accountable for the accuracy and integrity of the article.